Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone vs. Quetiapine on cognitive function in bipolar disorder
NCT00097032Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of risperidone and quetiapine in bipolar disorder (BD) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: To compare the treatment effects of risperidone and quetiapine on cognitive function due to sedation. Started Oct 2004; status: completed.
02
Drugs
risperidonequetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00097032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097032.